Αρχική World News Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced... World News Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor Από Ogkologos - 12 Οκτωβρίου, 2026 477 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the evERA study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR Stressed out – the cancer cells that survive chemotherapy, but at... 29 Απριλίου, 2021 Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among... 8 Νοεμβρίου, 2024 How My Navy Career Helped Shape My Positive Attitude During My... 16 Δεκεμβρίου, 2020 With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era 11 Ιουνίου, 2020 Φόρτωση περισσοτέρων HOT NEWS EMA Recommends Extension of Therapeutic Indications for Tremelimumab March is Multiple Myeloma Action Month Can Artificial Intelligence–Driven Chatbots Correctly Answer Questions about Cancer? Aspirin Being Investigated as Possible Treatment for Triple Negative Breast Cancer